UTILITY OF CARDIAC COMPUTED TOMOGRAPHY ANGIOGRAPHY TO EXCLUDE CLINICALLY SIGNIFICANT OBSTRUCTIVE DISEASE IN PATIENTS AFTER MYOCARDIAL PERFUSION IMAGING  by Patel, Nimish et al.
A70.E655
JACC March 9, 2010
Volume 55, issue 10A
 IMAGING AND DIAGNOSTIC TESTING 
UTILITY OF CARDIAC COMPUTED TOMOGRAPHY ANGIOGRAPHY TO EXCLUDE CLINICALLY SIGNIFICANT 
OBSTRUCTIVE DISEASE IN PATIENTS AFTER MYOCARDIAL PERFUSION IMAGING
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Sunday, March 14, 2010, 9:30 a.m.-10:30 a.m.
Session Title: CT Coronary Calcium and Noncoronary CT Applications
Abstract Category: CT Coronary Angiography
Presentation Number: 1037-223
Authors: Nimish Patel, Raveen S. Pal, Ferdinand Flores, Matthew J. Budoff, Department of Cardiology, Los Angeles County- Harbor-UCLA Medical 
Center, Torrance, CA, Los Angeles Biomedical Research Institute, Torrance, CA
Background: Patients with mildly abnormal or equivocal myocardial perfusion imaging (MPI) scans typically undergo diagnostic angiography or 
receive medical management for coronary artery disease (CAD). Catheterization is often required for either appropriate diagnosis or management. 
With its very high negative predictive rate, 64-detector cardiac computed tomography angiography (CCTA) has much potential in the role of ruling out 
clinically significant CAD. The purpose of this study was to analyze the cost implications of CCTA before catheterization in patients with abnormal or 
equivocal MPI scans.
Methods: Patients (n = 241) with abnormal or equivocal MPI scans underwent 64-detector CCTA instead of catheterization at the discretion of a 
treating physician. Using actual reimbursements for CT angiography and cardiac catheterization, we modeled the costs of two clinical algorithms: 
the standard approach utilizing cardiac catheterization in all patients immediately after abnormal MPI scan versus our proposed approach of using 
cardiac catheterization only in select patients with abnormal MPI scan and evidence of obstructive disease (>50% stenosis) on CCTA.
Results: 51 of 241 (21.6%) of the abnormal or equivocal nuclear tests revealed obstructive disease on CTA requiring catheterization. 158/241 
(65.5%) had no or minimal disease on CCTA, leading to a diagnosis of non-cardiac chest pain. Selective catheterization and CCTA demonstrated 
an average cost reduction of $1774 per patient. Sensitivity analysis revealed cost savings to be preserved even if up to 70% of the patient cohort 
undergoes catheterization after CCTA, and across a wide range of procedural costs.
Conclusions: CTA provided a robust reduction in the need for cardiac catheterization. CCTA after equivocal, mild or moderate abnormal MPI results 
in significant cost savings, and excludes obstructive coronary artery disease in almost 80% of patients.
